Home › NDC Lookup › RxCUI directory › RxCUI 2184147

Cilastatin 500 MG / imipenem 500 MG / relebactam 250 MG Injection [Recarbrio] — RxCUI 2184147

RxNorm drug concept · Semantic branded drug
RxCUI 2184147 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2184147
Official nameCilastatin 500 MG / imipenem 500 MG / relebactam 250 MG Injection [Recarbrio]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asRecarbrio 1.25 GM Injection; Recarbrio 500 MG / 500 MG / 250 MG Injection
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)96 prescriptions · 4 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Imipenem, Cilastatin, and Relebactam Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Recarbrio only comes as an IV infusion — there's no pill version. It's designed for serious infections that need high, reliable drug levels fast, and it works against some very tou...
  • Why am I getting this antibiotic instead of one in a pill form?
  • Most courses run between 4 and 14 days, depending on the type of infection, how serious it is, and how well you're responding to treatment. Your doctor will reassess as you go and...
  • How long will I need to be on this antibiotic?
📖 Read our full Imipenem, Cilastatin, and Relebactam Injection guide →

🕸️ Concept Web — How Cilastatin 500 MG / imipenem 500 MG / relebactam... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Cilastatin 500 MG / imipenem 500 MG / relebactam 250 MG Injection [Recarbrio] RxCUI 2184147

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 4

    The active substance itself — no strength, form, or brand attached yet.

    • Cilastatin 2540
    • Imipenem 5690
    • Relebactam 2184137
    • Cilastatin / imipenem / relebactam 2184141
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Recarbrio 2184143
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Cilastatin / imipenem / relebactam Injection 2184140
    • Cilastatin / imipenem / relebactam Injectable Product 2184139
    • Cilastatin / imipenem / relebactam Injection [Recarbrio] 2184145
    • Recarbrio Injectable Product 2184146
    • Injection 1649574
    • Injectable Product 1151126
  4. Clinical & branded drugs 5

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 16 of 16 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Cilastatin 500 MG / imipenem 500 MG / relebactam 250 MG [Recarbrio] SBDC · 2184144
  • Cilastatin / imipenem / relebactam Injection [Recarbrio] SBDF · 2184145
  • Recarbrio Injectable Product SBDG · 2184146
  • Recarbrio BN · 2184143

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2184147 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00006-3856-02 25 VIAL, SINGLE-DOSE in 1 CARTON (0006-3856-02) / 20 mL in... RECARBRIO Merck Sharp & Dohme LLC 2020-01-06
Observed labelers: Merck Sharp & Dohme LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J0742 Inj imip 4 cilas 4 releb 2mg 1 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.